Several studies have suggested an association of mannose-binding lectin (MBL) deficiency with infections. In this study, we investigated the association between MBL deficiency and invasive fungal disease (IFD) in hematologic malignancy patients receiving myelosuppressive chemotherapy or hematopoietic stem cell transplant. MBL levels were quantified at the start of treatment in 152 patients who were followed for 6 months and scored as developing IFD or not. Forty-five patients (29.6%) developed IFD, of which 21 (46.7% of IFD cases and 13.8% of patients) were proven or probable IFD. Fifty-nine (38.8%) had MBL levels o 1000 ng/mL. The rates of all IFD in patients with MBL levels below and above 1000 ng/mL were 33.9% and 26.9%, respectively (P = 0.356). The rates of proven or probable IFD in patients with MBL levels below and above 1000 ng/mL were 11.9% and 15.1%, respectively (P = 0.579). MBL levels o 1000 ng/mL were not predictors of death (P = 0.233). As expected, IFD was associated with death (P o 0.0001). Our findings indicate that MBL levels o1000 ng/mL were not associated with an increased risk of developing IFD or overall survival.
INTRODUCTION
Invasive fungal disease (IFD) is a leading cause of morbidity and mortality in patients with hematologic malignancies who undergo myelosuppressive chemotherapy or hematopoietic stem cell transplant (HSCT). [1] [2] [3] [4] In this patient population, prolonged immunodeficiency enhances susceptibility to developing IFD. Mannose-binding lectin (MBL), a member of the C-type lectin superfamily of microbe pattern recognition molecules, is a key component of innate immunity and is capable of recognizing and binding to carbohydrates of microorganisms leading to complement activation in an antibody-independent manner. MBL deficiency due to genetic polymorphism is common. 5 Even with the strong association between MBL genotype and serum MBL levels, patients with the same MBL genotype may vary up to 10-fold in functionally active MBL levels. 6, 7 Evidence from recent studies supports an association between MBL deficiency and increased risk of infections, but there are conflicting data. [8] [9] [10] [11] [12] Therefore, more studies of the association between low MBL levels and IFD in hematologic malignancy patients are needed.
In this study, we hypothesized that MBL levels below 1000 ng/mL will increase the risk of developing IFD and could therefore be useful in assessing clinical risk and guiding treatment. To test our hypothesis, we conducted a single institution retrospective study using a previously established storage bank of blood specimens from 152 patients with hematologic malignancies who received myelosuppressive chemotherapy and/or allogeneic HSCT between December 2001 and November 2006. We aimed to assess the association between low MBL levels that are o 1000 ng/mL and the development of proven or probable IFD in patients with hematologic malignancies undergoing myelosuppressive chemotherapy or allogeneic HSCT.
MATERIALS AND METHODS Patients
In this single-center, retrospective cohort study, an analysis of MBL levels in 152 patients with hematologic malignancies who underwent myelosuppressive chemotherapy and/or allogeneic HSCT between 2000 and 2005 at Shands at the University of Florida Medical Center was performed. All patients had no documented IFD before study enrollment. This study was approved by the University of Florida Institutional Review Board (IRB). All subjects provided written informed consent. The characteristics of this cohort are outlined in Table 1 . Clinical data were obtained by review of patients' charts from study entry through last follow-up in December 2011. Review of patients' charts incorporated outpatient and inpatient medical records, including laboratory and microbiological results, reports of radiological and histological examinations, discharge summaries, reports from primary care physicians and death certificates.
IFD
IFD was classified as proven, probable or possible based on the most recently revised definitions by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG). 13 Information on timing and type of antifungal prophylactic 1 and therapeutic treatments administered to patients was obtained.
Patients were followed for 6 months and scored as developing IFD or not.
MBL
Serum samples from all patients were collected before they received chemotherapy or HSCT between year 2000 and 2005 and stored them at − 70°C. An investigator who was blinded to any patient clinical data performed quantification of MBL levels using a sandwich-ELISA assay (Viracor-IBT Laboratories, MO, USA). MBL deficiency was defined as serum levels below 1000 ng/mL as previous research has shown this cutoff to differentiate well between patients with or without variant MBL genotypes. 6, 14, 15 Statistical analysis Patient characteristics were assessed using descriptive statistics to calculate means, s.d.'s and frequencies and to perform univariate tests. The relationship between MBL level and developing IFD was assessed by univariate analysis using Mann-Whitney, Kruskal-Wallis and χ 2 -tests. The effect of MBL level on the probability of developing IFD, when controlling for clinical co-variables of interest, was estimated using multivariate logistic regression. These co-variables included age at the start of chemotherapy or allogeneic HSCT, gender, race defined as being white vs all others, antifungal prophylaxis defined as receiving fluconazole vs all others, time from start of treatment to developing neutropenia, history of steroid use defined as receiving at least 1 mg/kg/day of prednisone dose equivalent for at least 1 week and type of conditioning regimens before allogeneic HSCT defined as myeloablative vs nonmyeloablative. Survival analyses including logistic regression and Cox Proportional Hazards models were used to test the effect of MBL level and IFD status on overall survival and whether MBL level has an effect on IFD-free survival time. SAS statistical software package was used for our statistical analysis. Table 1 . Fifty-nine of 152 patients (38.8%) had MBL levels below 1000 ng/mL. Fortyfive of 152 patients (29.6%) developed proven, probable or possible IFD during the 6 months follow-up period of whom 21 (46.7% of IFD cases and 13.8% of all patients) were proven or probable IFD (Table 1) .
RESULTS

Patient characteristics are described in
Effect of MBL levels on developing IFD Univariate analysis. The rates of all IFD in patients with MBL levels below and above 1000 ng/mL were 33.9% and 26.9%, respectively (P = 0.356). The mean MBL level was 2128 ng/mL in all patients and 1822 ng/mL in all IFD cases, respectively. Although the MBL level tended to be lower in the IFD group, the difference was not significant (P = 0.144). However, there were marginally significant differences in MBL levels across the different IFD groups (P = 0.078; Table 2 ). This nearly significant overall P-value appeared to be due to the differences between the possible IFD group and the other groups. P-values for group-to-group comparisons of the possible IFD group to the IFD-free, probable IFD and proven IFD groups were 0.014, 0.093 and 0.055, respectively. P-values for other group-to-group comparisons did not approach significance. The rates of proven or probable IFD in patients with MBL levels below and above 1000 ng/mL were 11.9% and 15.1%, respectively (P = 0.579). Mean MBL levels were actually lower in the IFD-free and possible IFD group when compared with the proven and probable IFD group (2085 ng/mL vs 2398 ng/mL, P = 0.429; Table 3 ).
Multivariate analysis. When all the clinical co-variables of interest were checked for association in order to guard against confounding in all patients, white patients and allogeneic HSCT recipients were more likely to have steroid use. In a multivariate analysis model with MBL level as a continuous variable, age, gender and steroid use as the only predictors, only steroid use was close to significance as a predictor of IFD (P = 0.052). It was estimated that patients who receive steroids had 2.2 times the odds of developing IFD than those who did not receive steroids (95% confidence interval (CI) = 0.993, 4.71). In a multivariate analysis model with MBL level as a dichotomous variable (MBL deficiency = MBL levels o 1000 ng/mL), age, gender and steroid use as the only predictors, again only steroid use was significant as a predictor of IFD (P = 0.045). It was estimated that patients who receive steroids had 2.2 times the odds of developing IFD than those who did not receive steroids (95% CI = 1.02, 4.80). In the remainder of the multivariate analyses models tested, the other clinical co-variables of interest were clearly not related to IFD with the exception of race. Race appeared to not directly be related to IFD, but rather was acting as a surrogate for steroid use due to the race difference in steroid use and therefore race was not a predictor of IFD when steroids were removed from the multivariate analysis model. When all the clinical co-variables of interest were checked for association in order to guard against confounding in allogeneic HSCT recipients, GvHD was closely correlated with steroid use. With all co-variables in a multivariate analysis model except for steroid use, GvHD and meyloablative vs nonmyeloablative conditioning were marginally significant predictors of IFD in allogeneic HSCT recipients. It was estimated that allogeneic HSCT recipients who had GvHD had 2.4 times the odds of developing IFD than those who did not have GvHD (95% CI = 0.956, 5.92, P = 0.063) and that allogeneic HSCT recipients who received myeloablative conditioning had 3.0 times the odds of developing IFD than those who received nonmyeloablative conditioning (95% CI = 0.831, 10.7, P = 0.094). In a multivariate analysis model with MBL levels, age, gender and GvHD as the only predictors, GvHD was a significant predictor of IFD in allogeneic HSCT recipients (P = 0.048). It was estimated that allogeneic HSCT recipients who had GvHD had 2.4 times the odds of developing IFD than those who did not have GvHD (95% CI = 1.01, 5.90).
Effect of MBL levels and IFD on survival In survival analyses, MBL level treated as a continuous variable was not a significant predictor of death (P = 0.181). MBL levels below 1000 ng/mL were not a predictor of death (P = 0.233). IFD was a highly significant predictor of death (P o 0.0001). It was estimated that patients who developed IFD had 10.1 times the odds of dying as patients who did not (95% CI = 3.93, 25.9). Estimated restricted mean survival time over the 6 months follow-up period in patients with MBL levels below and above 1000 ng/mL were 5. Association between MBL deficiency and IFD MM Riwes et al DISCUSSION IFD is associated with high morbidity and mortality in patients receiving myelosuppressive chemotherapy or allogeneic HSCT for their hematologic malignancies. [1] [2] [3] [4] Timely diagnosis and treatment of IFD is essential in improving survival. 16, 17 Therefore, it is important to identify patients who are at increased risk of developing IFD at the start of treatment for their hematologic malignancies in order to modify their clinical course.
Our retrospective cohort had a large number of IFD in patients receiving myelosuppressive and allogeneic HSCT with 45 of 152 patients having proven, probable or possible IFD, of which 21 were proven or probable IFD. Of note, the majority of the patients included in our study received fluconazole as antifungal prophylaxis. This is a rare cohort given the recent increase in use of mold-active antifungal therapy and the wider availability of newer non-invasive IFD diagnostic methods, which facilitate earlier diagnosis of IFD and allow for a preemptive treatment approach in hematologic malignancy patients. 18 Our findings demonstrated that there was no association between MBL levels o1000 ng/mL and IFD. Although MBL levels tended to be lower in the IFD positive than the IFD-free group, the difference was not significant. There was no association between MBL levels o1000 ng/mL and developing proven or probable IFD. On the contrary to what we set out to find, MBL levels tended to be higher in the proven and probable IFD group when compared with the possible IFD and IFD-free group. In our study, steroid use, GvHD and myeloablative conditioning regimens seemed to be predictors of IFD.
There are conflicting data about whether MBL deficiency is a good predictor of increased infection risk. In the study by Osthoff et al. 8 in 44 allogeneic HSCT recipients, there was an association between MBL levels o 1000 ng/mL and developing infections. However, only two of the patients in this study had fungal infections. In the study by Neth et al. 9 in 131 allogeneic HSCT recipients, there was an association between MBL levels o400 ng/mL and developing infections. However, only seven of the patients in this study had fungal pneumonia. On the contrary, in the study by Chaudhry et al. 11 in 110 pediatric allogeneic HSCT recipients, there was no association between MBL levels o400 ng/mL and developing infections. However, only eight of the patients in this study had IFD. Similarly, in the study by Rocha et al. 12 in 39 HLA identical sibling allogeneic HSCT recipients, there was no association between MBL gene polymorphisms and developing infections. However, only four of the patients in this study had IFD. In the abstract by Anaissie et al., 10 in 482 myeloma patients undergoing multiple cycles of antineoplastic chemotherapy including tandem autologous HSCT and consolidation chemotherapy after autologous HSCT, there was an association between MBL levels o 1000 ng/mL and invasive pulmonary aspergillosis. Fifty patients in this study had IFD. However, in this study there were no allogeneic HSCT recipients.
Not determining MBL genotypes in our study could appear as a limitation. However, serum MBL levels were shown to be a good surrogate for genetic MBL deficiency. 19 Previous studies showed that MBL levels o 1000 ng/mL differentiated well between patients with or without variant MBL genotypes. 6, 14, 15 MBL levels less than 1000 ng/mL were previously associated with infections in cancer and critical care patients. 8, 10, 20, 21 Due to these findings, MBL deficiency was defined as MBL levels o 1000 ng/mL in our study. 38.8% of our cohort of patients had MBL levels o1000 ng/mL and 9.9% had MBL levels o 100 ng/mL, which is similar to the general population. 22, 23 Moreover, despite our study Survival time in months Estimated survival probability P =0.215 Figure 1 . Survival time in months by MBL status over the 6 months follow-up. Estimated survival probability Figure 3 . IFD-free survival time in weeks by MBL status over the 6 months follow-up.
being a single-center retrospective study, to the best of our knowledge it is the largest study to date that examined the association between low MBL levels and IFD in hematologic malignancy patients receiving myelosuppressive chemotherapy or allogeneic HSCT. Having said that, the lack of association of MBL levels o 1000 ng/mL with developing IFD in our study does not necessarily mean that such an association is not important, given that in our very high-risk population, other factors such as steroid use and GvHD may be much more important risk factors for developing IFD.
